The amino terminus of JAK3 is necessary and sufficient for binding to the common γ chain and confers the ability to transmit interleukin 2-mediated signals
- 24 June 1997
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 94 (13) , 6910-6915
- https://doi.org/10.1073/pnas.94.13.6910
Abstract
JAK3 is a protein tyrosine kinase that specifically associates with the common γ chain (γc), a shared subunit of receptors for interleukin (IL) 2, 4, 7, 9, and 15. Patients deficient in either JAK3 or γc presented with virtually identical forms of severe combined immunodeficiency (SCID), underscoring the importance of the JAK3–γc interaction. Despite the key roles of JAK3 and γc in lymphocytic development and function, the molecular basis of this interaction remains poorly understood. In this study, we have characterized the regions of JAK3 involved in γc association. By developing a number of chimeric JAK3–JAK2 constructs, we show that the binding specificity to γc can be conferred to JAK2 by transferring the N-terminal domains of JAK3. Moreover, those JAK3–JAK2 chimeras capable of binding γc were also capable of reconstituting IL-2 signaling as measured by inducible phosphorylation of the chimeric JAK3–JAK2 protein, JAK1, the IL-2 receptor β chain, and signal transducer and activator of transcription 5A. Subsequent deletion analyses of JAK3 have identified the N-terminal JH7-6 domains as a minimal region sufficient for γc association. Furthermore, expression of the mutant containing only the JH7-6 domains effectively competed with full-length JAK3 for binding to γc. We conclude that the JH7-6 domains of JAK3 are necessary and sufficient for γc association. These studies offer clues toward a broader understanding of JAK-mediated cytokine signaling and may provide a target for the development of novel therapeutic modalities in immunologically mediated diseases.Keywords
This publication has 46 references indexed in Scilit:
- Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitorNature, 1996
- Developmental defects of lymphoid cells in Jak3 kinase-deficient miceImmunity, 1995
- Mutation of Jak3 in a Patient with SCID: Essential Role of Jak3 in Lymphoid DevelopmentScience, 1995
- Defects in B Lymphocyte Maturation and T Lymphocyte Activation in Mice Lacking Jak3Science, 1995
- Jak-STAT Signaling Induced by the v- abl oncogeneScience, 1995
- TRANSCRIPTIONAL RESPONSES TO POLYPEPTIDE LIGANDS: The JAK-STAT PathwayAnnual Review of Biochemistry, 1995
- Identification and purification of human stat proteins activated in response to interleukin-2Immunity, 1995
- Lymphocyte responses and cytokinesCell, 1994
- JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietinCell, 1993
- A protein tyrosine kinase in the interferon αβ signaling pathwayCell, 1992